picibanil and Vulvar-Neoplasms

Topics: Antineoplastic Agents; Child; Female; Humans; Lymphangioma; Picibanil; Sclerotherapy; Vulvar Neoplasms

Topics: Aged; Biological Products; Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Instillation, Drug; Mitomycin; Mitomycins; Picibanil; Vulvar Neoplasms

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Vaginal Neoplasms; Vincristine; Vulvar Neoplasms

The natural killer (NK) and antibody-dependent cellular cytotoxic (ADCC) activities were determined in peripheral blood lymphocytes of patients with gynecologic malignancy. The effects of a preparation of Streptococcus pyogenes (OK-432) and of interferon were determined. Patients with advanced cancer exhibited lower natural cytotoxicity than normal women. NK and ADCC activities were decreased following surgery and NK activity was decreased following chemotherapy. Radiation reduced the percentage of Leu-7-positive cells in the circulation of the patients. OK-432 augmented the NK activity of both healthy women and patients with early malignancy. Interferon was less effective than OK-432 in augmenting NK activity.

Topics: Adult; Aged; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cytotoxicity, Immunologic; Female; Flow Cytometry; Genital Neoplasms, Female; Humans; Interferon Type I; Killer Cells, Natural; Middle Aged; Ovarian Neoplasms; Picibanil; T-Lymphocytes; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms

A 59-year-old woman with recurrent malignant melanoma of the vulva has well responded to a combination of immunotherapy and chemotherapy. As an immunotherapy, 10KE OK-432 were injected into the tumor twice a week. Chemotherapeutic regimen consisted of intravenous push of 1 mg vincristine on day 1,100 mg dacarbazine from day 1 through 5 and 50 mg nitrosourea (ACNU) on day 5. This treatment was repeated with 4 week intervals. Before treatment, the patient had a 3 X 3 X 5 cm subcutaneous mass on the left vaginal wall near the introitus. Fifty percent objective reduction of the tumor was achieved 6 weeks after commencement of intralegional immunotherapy and chemotherapy, and the tumor almost disappeared 8 months later. At this time, the treatment was changed to a supportive immunotherapy with intramuscular injection of 1KE OK-432 twice a week. But the tumor began to enlarge 2 months later and the patient is now being treated with the same combination therapy. Major side effects were febrile episodes on the day of intratumor injection of OK-432 and nausea, vomiting during the interval of chemotherapy. Anemia was the main hematologic side effect, but leukocytopenia and thrombocytopenia were not severe. The combination of intratumor injection of OK-432 and chemotherapy seems to be effective for the treatment of malignant melanoma.

Topics: Adjuvants, Immunologic; Antineoplastic Agents; Biological Products; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections; Melanoma; Middle Aged; Mitomycin; Mitomycins; Picibanil; Vincristine; Vulvar Neoplasms